Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVEROLIMUS Cause Systemic inflammatory response syndrome? 29 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Systemic inflammatory response syndrome have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 0.1% of all adverse event reports for EVEROLIMUS.

29
Reports of Systemic inflammatory response syndrome with EVEROLIMUS
0.1%
of all EVEROLIMUS reports
12
Deaths
27
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From EVEROLIMUS?

Of the 29 reports, 12 (41.4%) resulted in death, 27 (93.1%) required hospitalization, and 13 (44.8%) were considered life-threatening.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 29 reports have been filed with the FAERS database.

What Other Side Effects Does EVEROLIMUS Cause?

Death (5,090) Malignant neoplasm progression (3,789) Diarrhoea (3,061) Fatigue (2,946) Stomatitis (2,692) Nausea (2,079) Dyspnoea (1,925) Drug ineffective (1,837) Pyrexia (1,664) Decreased appetite (1,633)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which EVEROLIMUS Alternatives Have Lower Systemic inflammatory response syndrome Risk?

EVEROLIMUS vs EVOLOCUMAB EVEROLIMUS vs EXELON EVEROLIMUS vs EXEMESTANE EVEROLIMUS vs EXENATIDE EVEROLIMUS vs EXFORGE

Related Pages

EVEROLIMUS Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome EVEROLIMUS Demographics